MDA.TO stock jumped intraday to CAD 43.74, a 4.02% rise on 04 Mar 2026 after the company posted stronger full-year results and held a Q4 earnings call. Investors focused on a 51.20% revenue increase to CAD 1.63 billion and adjusted EPS of CAD 1.46. We summarise the earnings beat, intraday price action on the TSX, valuation metrics and a modelled outlook to help position this move in market context.

MDA.TO stock: Earnings highlights and what changed

MDA Ltd. (MDA.TO) reported full-year revenue of CAD 1.63 billion, up 51.20% year-over-year, and GAAP net income of CAD 108.50 million or CAD 0.84 per share. Management also disclosed adjusted earnings of CAD 189.90 million or CAD 1.46 per share. The results beat street expectations and underpinned stronger near-term visibility for satellite and geointelligence contracts. For the official release and call transcript, see Nasdaq and Seeking Alpha coverage and the Reuters summary source source.

MDA.TO stock: Intraday market reaction and volume

Shares opened at CAD 40.98 and traded between CAD 39.28 and CAD 43.78 during the session, closing this snapshot at CAD 43.74. Volume reached 1,181,916 shares versus an average of 986,377, reflecting above-average interest. The intraday gain of 4.02% tracked strong buying after the earnings call and pushed the stock above its 50-day average of CAD 33.83 and 200-day average of CAD 33.50.

MDA.TO stock: Valuation and core financials

MDA’s trailing EPS sits at CAD 0.85 and the trailing P/E is 47.66, which is premium to the Industrials sector average P/E of 23.33 in Canada. Key ratios show price-to-sales of 3.51, price-to-book of 3.88, and a free cash flow yield of 10.55% (0.1055). The company reported operating cash flow per share of CAD 5.86 and free cash flow per share of CAD 4.36, supporting a valuation that prices growth and recurring government contracts.

MDA.TO stock: Meyka AI grade and analyst context

Meyka AI rates MDA.TO with a score out of 100: 77.93, Grade B+, Suggestion BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Third-party firm scores show a recent company rating of B / Neutral dated 03 Mar 2026, highlighting mixed views on P/E but strong DCF signals.

MDA.TO stock: Technicals and risk indicators

Technical indicators show momentum but near-term overbought signals. RSI is 68.45 and CCI is 127.66, while ADX at 34.83 signals a strong trend. Volatility measured by ATR is 1.86. Balance-sheet risks include a current ratio of 0.55 and receivables days at 125.37, which raise working-capital sensitivity in contract billing cycles.

MDA.TO stock: Outlook and model forecasts

Meyka AI’s forecast model projects a yearly target of CAD 44.72, implying a near-term upside of 2.24% versus the current CAD 43.74. The model also shows a 3-year target of CAD 67.62, implying longer-term upside of 54.60%. Consensus price targets vary, with MarketBeat listing CAD 45.43. Forecasts are model-based projections and not guarantees.

Final Thoughts

MDA.TO stock moved higher intraday on 04 Mar 2026 after a clear earnings beat and stronger revenue momentum. The key drivers are a 51.20% jump in revenue to CAD 1.63 billion, adjusted EPS of CAD 1.46, and accelerating free cash flow per share of CAD 4.36. Valuation remains rich versus industrial peers with a trailing P/E of 47.66, but cash-flow metrics and backlog visibility support upside. Meyka AI’s forecast model projects CAD 44.72 for the year, an implied upside of 2.24%, while a three-year scenario points to CAD 67.62. Investors should weigh near-term overbought technicals and a tight current ratio against contract growth and defense/geospatial tailwinds. For more data and live updates visit the Meyka stock page for MDA.TO and review the full earnings release on Nasdaq and Reuters for primary details.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.